SestaMIBI scintigraphy in diagnosis of ovarian cancer’s relapse
Agnieszka Timorek-Lemieszczuk1, Ewa Kurowska-Mroczek1, Beata Osuch1, Maciej Jakuciński2
Ovarian cancer is the main cause of mortality among women suffering from malignant genital system cancer in Poland. Early detection of possible cancer recurrence after combined first-line therapy is necessary to launch adequate additional treatment with the best result for patient. Elevated concentration of CA-125 may precede clinical symptoms of reoccurrence even by a few months. A fusion of a functional study such as the positron emission tomography with a morphological study of computer tomography (PET-CT) allows for obtaining precise data about metabolic activity as well as anatomical evaluation of how advanced the cancer process is. Aim of the study: To compare the value of scintigraphy in which Tc-99m sestaMIBI is used and the value of PET-CT in early detection of cancer recurrence among women diagnosed with ovarian cancer. Material and methods: Fourteen patients diagnosed with ovarian cancer in clinical stages from IC to IIIC underwent scintigraphy (using Tc-99m sestaMIBI) of pelvis minor and abdomen as well as PET-CT of the whole body. Diagnostic value of the Tc-99m sestaMIBI scintigraphy and PET-CT was evaluated on the basis of sensitivity, specificity, and positive and negative predictive value of these tests. Results: Functional studies such as the Tc-99m sestaMIBI scintigraphy and the positron emission tomography linked with computer tomography, can be especially useful in a oncological gynecology in cases that cannot be equivocally decided using other available diagnostic methods. However, our results will require further investigation in which a greater number of patients in a study group should be used.